Bryn Pharma, LLC raised $17.5 million to fund government approval and the commercialization of an epinephrine nasal spray, the company announced in a press release Thursday.

Bryn Intranasal Epinephrine Spray, or BRYN-NDS1C, is designed to hold two doses of epinephrine in one device, eliminating the need for patients to carry two epinephrine auto-injectors in case of an allergic reaction.

The Food and Drug Administration granted fast track designation to BRYN-NDS1C in early 2019, the company said in the statement.

“This financing follows our rapid advancement of the development and clinical testing of BRYN-NDS1C,” said David Dworaczyk, CEO of Bryn Pharma. “The additional capital will be used to prepare for the rapid commercialization of the product once approved by the FDA.”

The company raised $15 million from new and existing investors and $2.5 million from a corporate collaborator for the project, the company said.

Founded in 2016, Bryn Pharma is a privately held pharmaceutical company focused on creating a bidose epinephrine nasal spray to treat anaphylaxis.